Xinlitai: 3-5 new products are expected to enter the clinic this year.

FAP, April 17 (FAP)-in a survey conducted by investors, Xinlitai said that the company currently has seven III phase clinical and listing applications, and eight I/II phase clinical applications. It is expected that 3-5 new products will enter the clinic this year, and at least 2-3 IND applications will be filed each year in the future.